This content is only available as a PDF.

Competing Interests

Source of Support: Vivek Subbiah disclosed research funding/grant support for clinical trials from FUJIFILM Pharmaceuticals USA, Inc., Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-Sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Loxo Oncology, Medimmune, Altum, Dragonfly Therapeutics, Takeda and Roche/Genentech, National Comprehensive Cancer Network, NCI-CTEP. Supported by UT MD Anderson Cancer Center (P30 CA016672). Travel assistance was provided by Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte, US-FDA. Vivek Subbiah disclosed a consultancy advisory role for Helsinn, LOXO Oncology/Eli Lilly, Daichi Sankyo, R-Pharma US, INCYTE, Medimmune, Novartis. Aakash Desai has nothing to disclose.

Conflict of Interest: None.

Article PDF first page preview

Article PDF first page preview